Feedback
Settings

Settings

Goto Application

83,669 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(NYHBQMYGNKIUIF-UUOKFMHZSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 8,367
1.WO/2025/259679IMPACT OF ADIPOCYTE-RELEASED ADIPOMES ON CARDIAC METABOLIC AND IMMUNE REGULATION IN CHAGAS CARDIOMYOPATHY AND IN A BREAST CANCER MODEL
WO - 18.12.2025
Int.Class C12Q 1/6809
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6809Methods for determination or identification of nucleic acids involving differential detection
 Appl.No PCT/US2025/033015 Applicant HACKENSACK MERIDIAN HEALTH, INC. Inventor NAGAJYOTHI, Jyothi F.
In the body, adipose tissue is comprised of adipocytes as well as various other cell types, including immune cells, that may contribute to the overall extracellular vesicle pool. Adiponectin, a protein hormone produced by fat cells, and fatty acid binding protein 4 (FABP4) were selected as markers to isolate adipocyte- specific EVs/adipomes from the total pool of white adipose tissue-derived EVs based on in vitro data showing that they colocalized with Annexin V, an apoptosis marker, on the surface of budding apoptotic bodies. Intact L-adipomes (large- adipomes) and S-adipomes (small-adipomes) were successfully and selectively enriched from large-EVs and small-EVs, respectively. Immunoblotting analysis confirmed the presence of adiponectin, FABP4, Annexin V, and perilipin in both L- and S-adipomes, providing further evidence of their adipocyte origin.
2.WO/2025/259875NOVEL ANTIBODY OLIGONUCLEOTIDE DRUG CONJUGATES CONTAINING GEMCITIBINE FOR PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF USE AND TREATMENT
WO - 18.12.2025
Int.Class A61K 31/713
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
713Double-stranded nucleic acids or oligonucleotides
 Appl.No PCT/US2025/033345 Applicant SIRNAOMICS, INC. Inventor LU, Patrick
Antibody-oligonucleotide drug conjugates (AODC) targeting CHK1 and/or WEE1 are provided for use in pharmaceutical compositions and methods of treating various cancers. AODCs comprise an antibody, a peptide linker and an oligonucleotide containing GEM moieties. In some embodiments, the oligo comprises a double stranded RNA molecule, which comprises one or more gemcitabine (GEM) moieties replacing certain cytidine nucleotides or other nucleotides. When the sense strand is separated from the antisense strand, one or both of which contain at least one GEM moiety, the sense strand releases its GEM moieties and together with the CHK1-siRNA (containing GEM), exerts a synergistic effect that exceeds the effects of either the released GEM moieties or the CHK1-siRNA-GEM construct alone to silence the CHK1 gene. In some embodiments the RNA molecule of the AODC is an mxRNA containing GEM moieties or an muRNA construct with GEM moieties in one or both antisense strands, targeting both CHK1 and WEE1.
3.WO/2025/259914CD24 CAR-T CELLS FOR TREATMENT OF HEMATOPOIETIC AND SOLID TUMORS
WO - 18.12.2025
Int.Class A61K 40/31
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
40Cellular immunotherapy
30characterised by the recombinant expression of specific molecules in the cells of the immune system
31Chimeric antigen receptors
 Appl.No PCT/US2025/033412 Applicant UNIVERSITY OF VIRGINIA PATENT FOUNDATION Inventor TAO, Jianguo
Chimeric antigen receptors that bind to CD24, optionally further including CXCR3 or IL-15, and optionally further including EGFRt, polynucleotides encoding the receptors, cells comprising the polynucleotides, and methods of treating cancers using said chimeric antigen receptors or cells are disclosed.
4.WO/2025/259780POLYPEPTIDES AND METHODS FOR MODIFYING NUCLEIC ACIDS
WO - 18.12.2025
Int.Class C12N 15/52
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
52Genes encoding for enzymes or proenzymes
 Appl.No PCT/US2025/033195 Applicant THE UNIVERSITY OF CHICAGO Inventor TANG, Weixin
Aspects herein include RNA-base-editing proteins linked to RNA-targeting proteins, which can allow for targeted editing of an RNA molecule. Aspects herein include systems and compositions comprising the base-editing and targeting proteins along with methods of their use.
5.WO/2025/259931COMPOSITIONS AND METHODS FOR RNA CIRCULARIZATION
WO - 18.12.2025
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
 Appl.No PCT/US2025/033446 Applicant ORBITAL THERAPEUTICS, INC. Inventor VENKATARAMANAN, Srivats
The present invention provides nucleic acids and methods for making circular RNAs (circRNAs), and circular RNAs, compositions and methods of use thereof. The present invention uses selected self-splicing intron sequences (e.g., intronic sequences derived from self-splicing Group I or Group II introns) to produce circular RNAs. These self-splicing intron sequences described herein mediate efficient circularization of a linear RNA sequence.
6.WO/2025/259976DEAMINATION POLYPROTEINS AND METHODS OF USE THEREOF
WO - 18.12.2025
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
 Appl.No PCT/US2025/033535 Applicant PIONEER HI-BRED INTERNATIONAL, INC. Inventor BIGELYTĖ, Greta
The present disclosure provides dimeric deamination polyproteins comprising a first nucleotide deaminase, a second nucleotide deaminase, a first nuclease-active Cas-alpha 10 polypeptide, and a nuclease-active second Cas-alpha 10 polypeptide. Also disclosed are methods of modifying a double-stranded DNA target site and methods of multiplexed editing using a deamination polyprotein and guide polynucleotides, wherein a dimeric deamination polyprotein and the guide polynucleotide form a complex that recognizes and binds to a dsDNA target site.
7.WO/2025/259726METHODS FOR SEPARATING DIASTEREOMERS OF DOUBLE-STRANDED OLIGONUCLEOTIDES
WO - 18.12.2025
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
 Appl.No PCT/US2025/033091 Applicant AMGEN INC. Inventor GUAN, Lianxiu
Provided herein are methods of separating diastereomers of a double-stranded oligonucleotide. In exemplary embodiments, the method comprises: (a) applying a sample comprising diastereomers of a double-stranded oligonucleotide to an anion exchange (AEX) chromatographic matrix, wherein each strand of the double-stranded oligonucleotide comprises at least one phosphorothioate internucleotide linkage; and (B) applying a mobile phase to the AEX chromatographic matrix to elute the diastereomers of the double-stranded oligonucleotide from the matrix, wherein the mobile phase comprises a buffer and an elution salt and has a pH of greater than 10.
8.WO/2025/259592THERAPEUTIC PREDICTIVE RESPONSE SIGNATURES AND USES THEREOF IN CANCER PATIENTS
WO - 18.12.2025
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
 Appl.No PCT/US2025/032861 Applicant GENECENTRIC THERAPEUTICS, INC. Inventor MAYHEW, Gregory Michael
Provided herein are pharmacological response activation signatures for use in methods and compositions for predicting the response of a subject suffering from cancer to treatment with select inhibitors.
9.WO/2025/258992METHOD FOR PRODUCING HEMOSTATIC MEDICAL NANOFIBER FOR INTERVENTIONAL PROCEDURES AND MEDICAL NANOFIBER PRODUCED THEREBY
WO - 18.12.2025
Int.Class D01F 8/18
DTEXTILES; PAPER
01NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
FCHEMICAL FEATURES IN THE MANUFACTURE OF MAN-MADE FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
8Conjugated, i.e. bi- or multicomponent, man-made filaments or the like; Manufacture thereof
18from other substances
 Appl.No PCT/KR2025/007966 Applicant IMT INC. Inventor PARK, Jun-Kyu
The present invention relates to a method for producing hemostatic medical nanofibers for interventional procedures, the method comprising: (a) a step for producing a spinning solution for fiber production by adding C1-7 alcohol to a mixed aqueous solution in which an aqueous polyalkylene oxide solution and a hydrophilic polymer additive are mixed; and (b) a step for electrospinning the spinning solution through a dedicated catheter connected to a frictional static electricity-based portable nanofiber production device.
10.WO/2025/259817METHODS FOR REDUCED TISSUE DAMAGE FROM RADIOPHARMACEUTICALS WITH SUPEROXIDE-REDUCING AGENT
WO - 18.12.2025
Int.Class A61K 51/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier
 Appl.No PCT/US2025/033252 Applicant GALERA LABS, LLC Inventor ZEPEDA-OROZCO, Diana
A method of treating, reducing the risk of, and/or preventing damage to normal tissue associated with exposure to radionuclides arising from treatment or diagnosis with radiopharmaceuticals in a mammalian subject in need thereof, is provided. The method includes administering to the subject an amount of a radiopharmaceutical that is effective for treatment or diagnosis, and prior to, concomitantly with, or after administration of the radiopharmaceutical, providing a superoxide-reducing agent to reduce levels of superoxide in the subject to a level that is sufficient to treat, reduce the risk of, and/or prevent damage to normal tissue from the radiopharmaceutical.
# -